Delcath Systems (NASDAQ:DCTH) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Delcath Systems (NASDAQ:DCTH – Get Rating) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

A number of other brokerages have also issued reports on DCTH. Canaccord Genuity Group cut their target price on Delcath Systems from $17.00 to $14.00 in a research report on Monday, November 21st. BTIG Research lowered their price target on Delcath Systems to $19.00 in a report on Tuesday, November 15th.

Delcath Systems Stock Performance

Delcath Systems stock opened at $3.88 on Tuesday. The stock’s 50 day moving average price is $3.33 and its 200 day moving average price is $3.56. Delcath Systems has a one year low of $2.34 and a one year high of $7.75. The firm has a market capitalization of $38.98 million, a PE ratio of -1.02 and a beta of 0.87.

Delcath Systems (NASDAQ:DCTH – Get Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. Delcath Systems had a negative return on equity of 1,396.28% and a negative net margin of 757.05%. The company had revenue of $0.91 million for the quarter, compared to analyst estimates of $0.82 million. During the same period in the prior year, the company posted ($0.94) EPS. On average, analysts forecast that Delcath Systems will post -3.77 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Rosalind Advisors, Inc. purchased 15,215 shares of the stock in a transaction dated Wednesday, December 14th. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $55,078.30. Following the acquisition, the director now owns 459,315 shares of the company’s stock, valued at $1,662,720.30. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 16.76% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Delcath Systems by 5.7% during the 1st quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock worth $2,309,000 after buying an additional 19,605 shares during the last quarter. Cibc World Market Inc. grew its stake in Delcath Systems by 4.0% during the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock worth $568,000 after buying an additional 3,432 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Delcath Systems during the 1st quarter worth $75,000. Finally, Millennium Management LLC bought a new position in Delcath Systems during the 2nd quarter worth $40,000. 25.66% of the stock is currently owned by institutional investors.

About Delcath Systems

(Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.